Open AccessUse of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors
Author(s) -
Jonas Apitzsch,
Frederik A. Verburg,
Felix M. Mottaghy,
Alexander Heinzel
Publication year - 2021
Publication title -
diagnostic and interventional radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 43
eISSN - 1305-3612
pISSN - 1305-3825
DOI - 10.5152/dir.2021.19424
Subject(s) - medicine , neuroendocrine tumors , nuclear medicine , pet ct , radiology , contrast (vision) , positron emission tomography , artificial intelligence , computer science
Studies have demonstrated that positron emission tomography/computed tomography (PET/CT) with Gallium-68 (68Ga)-labeled somatostatin analogues are effective at detecting metastatic disease in neuroendocrine tumors (NET), especially extrahepatic metastases. However, PET in combination with full-dose contrast-enhanced CT (ceCT) exposes patients to higher radiation (~25 mSv). The use of non-contrast-enhanced low-dose CT (ldCT) can reduce radiation to about 10 mSv and may avoid contrast-induced side effects. This study seeks to determine whether ceCT could be omitted from NET assessments.